EPISODE · May 4, 2026 · 1 MIN
Eli Lilly's GLP-1 Drugs Ignite Growth
from The Daily News Now! Business
Eli Lillys Q1 2026 earnings surged 56% to $19.8 billion, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound, which raked in $12.8 billion. Mounjaros sales are balanced between U.S. and international markets, while Zepbound, a weight loss champ, is primarily domestic. Despite a 10% share drop and high valuation, investors are optimistic about long-term wins, especially with recent approvals and promising trials for new drugs. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/fa88aa05b1ad0e85
NOW PLAYING
Eli Lilly's GLP-1 Drugs Ignite Growth
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m